Neogen Corp

Neogen Corp(NEOG)股票分析

$11.810

-0.443 (-3.75%)收盘时

Loading chart…
最高
12.450
开盘
12.270
成交量加权均价
11.98
成交量
2.46M
市值
3.46B
最低
11.680
成交额
29.46M
企业价值/息税折旧摊销前利润(TTM)
29.67

Neogen Corporation and subsidiaries are engaged in developing, manufacturing and marketing a diverse line of products and services dedicated to food and animal safety. The Company has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. Its segments include Food Safety and Animal Safety. The Food Safety segment is primarily engaged in the development, production and marketing of diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation. The Animal Safety segment is primarily engaged in the development, production and marketing of products dedicated to animal safety, including a complete line of consumable products marketed to veterinarians and animal health product distributors. This segment also provides genomic identification and related interpretive bioinformatic services.

AI 分析 of Neogen Corp (NEOG)

买入

Neogen Corp is a good buy right now due to its recent fiscal guidance upgrade, raising revenue expectations to between $885 million and $890 million, which reflects strong confidence in future performance. Additionally, the stock has shown a remarkable year-to-date change of +68.71% and a one-year change of +100.51%, indicating robust growth. However, a key risk is the current RSI of 40.44, suggesting that the stock may be approaching oversold territory, which could lead to short-term volatility.

分析师评级(7)

-30.82% 下跌空间
持有
0 买入
7 持有
0 卖出
当前: 11.81
最低
6.50
平均
8.17
最高
10.00

Guggenheim

2026-09-30

目标价

$14

买入

Guggenheim

2026-09-29

目标价

$12

买入

Piper Sandler

2026-08-26

目标价

$14

增持

Piper Sandler

2026-08-03

目标价

$13

中性

Guggenheim

2026-01-09

目标价

$12

买入

估值指标

Neogen Corp(NEOG)当前预期市盈率为 16.00,5 年平均预期市盈率为 31.43。

预期市盈率

合理
5 年均值 P/E
31.43
当前P/E
16.00
高估
46.99
低估
15.87

预期 EV/EBITDA

高估
5 年均值 EV/EBITDA
16.74
当前EV/EBITDA
29.67
高估
25.28
低估
8.20

预期市销率

合理
5 年均值 P/S
3.61
当前P/S
3.06
高估
5.33
低估
1.89

Alphio AI 对 NEOG 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%NEOG

$7.55

情景价格

基

基准

基准 · 50%NEOG

$6.69

情景价格

悲

悲观

悲观 · 25%NEOG

$6.11

情景价格

持有 NEOG 的大户

G

Gates Capital Management, Inc.

+ 持有NEOG

-7.42%

3个月收益率

事件时间线

2026-10-07 (ET)

16:30:00

Major Averages Decline After Fed Meeting Minutes Release

12:30:00

Major Averages Broadly Lower as 10-Year Treasury Yield Rises to 5.356%

09:00:00

Stock Futures Point to Lower Open as Tech Stocks Weigh

2026-10-06 (ET)

20:00:00

Nasdaq and S&P 500 Hit Record Highs

16:30:00

Neogen Reports Q1 Revenue of $222.8M, Beating Expectations

资讯

NEOG 常见问题 —— 由 Alphio AI 解答

Neogen Corporation and subsidiaries are engaged in developing, manufacturing and marketing a diverse line of products and services dedicated to food and animal safety. The Company has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. Its segments include Food Safety and Animal Safety. The Food Safety segment is primarily engaged in the development, production and marketing of diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation. The Animal Safety segment is primarily engaged in the development, production and marketing of products dedicated to animal safety, including a complete line of consumable products marketed to veterinarians and animal health product distributors. This segment also provides genomic identification and related interpretive bioinformatic services. It operates in the Healthcare sector (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry).

Neogen Corp is a good buy right now due to its recent fiscal guidance upgrade, raising revenue expectations to between $885 million and $890 million, which reflects strong confidence in future performance. Additionally, the stock has shown a remarkable year-to-date change of +68.71% and a one-year change of +100.51%, indicating robust growth. However, a key risk is the current RSI of 40.44, suggesting that the stock may be approaching oversold territory, which could lead to short-term volatility.

7 analysts cover NEOG: 0 rate it Buy, 7 Hold and 0 Sell. The average price target is 8.17.

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易